Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HNF4A | P41235 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088776 | 0.92 | TSHR (0.50) | TSHRTP53CES2CES1SMN1; SMN2 | |
| SCHEMBL3765025 | 0.82 | SMN1; SMN2 (0.45) | CES2CES1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9451018 | 0.81 | MEN1 (0.41) | TSHRSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL8185981 | 0.81 | TSHR (0.46) | TSHRTP53CES2CES1SMN1; SMN2 | |
| SCHEMBL8178904 | 0.79 | MEN1 (0.60) | TSHRTP53CES2CES1SMN1; SMN2 | |
| SCHEMBL6420071 | 0.79 | NPC1 (0.68) | TSHRSMN1; SMN2NPC1RAB9AKMT2A | |
| Terephthalic Acid SCHEMBL3895453 | 0.79 | TSHR (0.67) | TSHRTP53CES2CES1SMN1; SMN2 | |
| Terephthalic Acid SCHEMBL4091430 | 0.79 | TSHR (0.67) | TSHRTP53CES2CES1SMN1; SMN2 | |
| SCHEMBL28341270 | 0.79 | ALDH1A1 (0.55) | SMN1; SMN2MEN1KMT2AHPGDPOLB | |
| SCHEMBL14966664 | 0.78 | PRKAG1 (0.47) | TSHRTP53MEN1KMT2AHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233977-A | Prodrugs of boron compounds and their use in the treatment of bacterial infections | 上海盟科药业股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119233823-A | Method and use of boron compounds for treating nontuberculous mycobacterial infections and pharmaceutical compositions for treating the same | 上海盟科药业股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240279247-A1 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | claimed |
| US-20240269155-A1 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | MICURX PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | claimed |
| EP-4384527-A1 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| EP-4384185-A1 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | Micurx Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2023246841-A1 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-12-28 | — | — | WO | claimed |
| WO-2023246842-A1 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-12-28 | — | — | WO | claimed |
| CN-119233823-B | Method and use of boron compounds for treating nontuberculous mycobacterial infections and pharmaceutical compositions for treating the same | Shanghai Mengke Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119233977-A | Prodrugs of boron compounds and their use in the treatment of bacterial infections | 上海盟科药业股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119233823-A | Method and use of boron compounds for treating nontuberculous mycobacterial infections and pharmaceutical compositions for treating the same | 上海盟科药业股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118652243-A | Peroxisome proliferator-activated receptor (PPARs) agonist, preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-09-17 | — | — | CN | disclosed |
| US-20240279247-A1 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240269155-A1 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | MICURX PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269155-A1 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | TBCB, ABCB7, BPGM | TSHR 1708/4885TP53 2005/4885CES2 1311/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | TSHR 2806/4885TP53 3639/4885CES2 3037/4885 |
| US-20240279247-A1 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | BLVRB, UGT2B7, BPGM | TSHR 3100/4885TP53 1862/4885CES2 775/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | TSHR 2862/4885TP53 3761/4885CES2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.